In summary, we for the first time demonstrate the involvement of miR-665-3p in promoting NAFLD via inactivating FNDC5/AMPKα pathway, and inhibiting miR-665-3p may provide novel therapeutic strategies to treat NAFLD. The gene discussed is FNDC5; the disease is metabolic dysfunction-associated steatotic liver disease.